Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS: * Histologically\* or cytologically\* confirmed non-small cell lung cancer * Any histology, except squamous cell carcinoma, allowed * Mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible * No histology in close proximity to a major vessel or cavitation NOTE: \*Histologic or cytologic elements may be established on metastatic tumor aspirates or biopsy * Meets 1 of the following stage criteria: * Stage IIIB disease (with malignant pleural effusion) * Stage IV disease * Recurrent disease * Measurable or non-measurable disease * No known CNS metastases by CT scan or MRI PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-1 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count \> 1,500/mm\^3 * Platelet count \> 100,000/mm\^3 * No history of hemorrhagic disorders Hepatic * Bilirubin \< 1.5 mg/dL * AST and ALT \< 5 times upper limit of normal * INR \< 1.5 * PTT normal Renal * Creatinine clearance ≥ 45 mL/min * Urine protein:creatinine ≤ 1.0 by spot urinalysis Cardiovascular * No myocardial infarction within the past 6 months * No New York Heart Association class II-IV congestive heart failure * No unstable angina pectoris * No serious cardiac arrhythmia requiring medication * No stroke within the past 6 months * No peripheral vascular disease ≥ grade 2 * No uncontrolled hypertension (i.e., blood pressure ≥ 150/100 mm Hg) * Patients with a history of hypertension allowed provided blood pressure is well controlled on a stable regimen of anti-hypertensive therapy * No history of thrombotic disorders * No other clinically significant cardiovascular disease Pulmonary * No history of gross hemoptysis, defined as bright red blood of a ½ teaspoon or more Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Must be willing and able to take daily oral folic acid, intermittent vitamin B\_12 injections, and corticosteroid premedication * No ongoing or active infection * No serious, non-healing wound, ulcer, or bone fracture * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * No psychiatric illness or social situation that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy * More than 3 weeks since prior immunotherapy Chemotherapy * No prior systemic chemotherapy Endocrine therapy * More than 3 weeks since prior hormonal therapy Radiotherapy * See Disease Characteristics * More than 3 weeks since prior radiotherapy Surgery * More than 4 weeks since prior major surgery * More than 1 week since prior minor surgery, fine needle aspiration, or core biopsy * No concurrent major surgery Other * Recovered from all prior therapy * More than 4 weeks since prior and no concurrent participation in another experimental drug study * No aspirin or other nonsteroidal anti-inflammatory drug (NSAID) 2 days before and 2 days after each pemetrexed disodium infusion (5 days before and 2 days after each pemetrexed disodium infusion for NSAIDs with a long half-life \[e.g., naproxen, rofecoxib, or celecoxib\]) * No concurrent therapeutic anticoagulation * Concurrent prophylactic anticoagulation for venous access devices allowed provided requirements for INR and PTT are met * No concurrent administration of any of the following: * Chronic daily treatment with aspirin (\> 325 mg per day) * NSAIDs known to inhibit platelet function, including any of the following: * Dipyridamole * Ticlopidine * Clopidogrel * Cilostazol